Applied Clinical Trials

Applied Clinical Trials
  • 0.0 (0)
  • Life Sciences

Go behind the pages of Applied Clinical Trials

  1. 7h ago

    ACT Brief: Trial Execution Cost Burden and Protocol Variability, Real-World Oncology Data Curation Complexity, and Real-Time Analytics Datapoint Scale

    In today's ACT Brief, we examine the $500,000-per-day cost of execution delays and protocol variance at the point of care, why oncology real-world data requires hybrid clinical expertise with technology, and scaling challenges as trial data volumes continue to grow.

    ACT Brief: Trial Execution Cost Burden and Protocol Variability, Real-World Oncology Data Curation Complexity, and Real-Time Analytics Datapoint Scale

  2. 1d ago

    ACT Brief: Real-Time Monitoring Through Quick Wins, Consumer Wearable Validation Requirements, and Replimune RP1 Efficacy Data Advancement

    In today's ACT Brief, we examine how a gradual, win-driven strategy scales real-time monitoring adoption, why consumer wearables need rigorous fit-for-purpose validation, and an FDA committee's favorable vote on Replimune's oncolytic virus combination therapy.

    ACT Brief: Real-Time Monitoring Through Quick Wins, Consumer Wearable Validation Requirements, and Replimune RP1 Efficacy Data Advancement

  3. 4d ago

    ACT Brief: Real-Time Review Ecosystem Approach, AI Infrastructure Before Tools, and FDA Peptide Compounding Access

    In today's ACT Brief, we examine why real-time monitoring scales only through coordinated ecosystem efforts, how organizational failures not models explain weak AI results, and FDA's advisory panel peptide compounding decision.

    ACT Brief: Real-Time Review Ecosystem Approach, AI Infrastructure Before Tools, and FDA Peptide Compounding Access

  4. 5d ago

    ACT Brief: ESG as Commercial Selection Factor, Real-Time Monitoring Scale Readiness, and FDA Cancer Trial Eligibility Expansion

    In today's ACT Brief, we examine how sustainability is shifting from compliance to a procurement driver, what infrastructure gaps remain in FDA's real-time pilot model, and regulatory guidance targeting unnecessarily restrictive cancer trial criteria.

    ACT Brief: ESG as Commercial Selection Factor, Real-Time Monitoring Scale Readiness, and FDA Cancer Trial Eligibility Expansion

  5. 6d ago

    Beyond Compliance: YPrime's Paulo Limgenco on Moving ESG From Reporting to Real Business Value

    In this pilot episode of Beyond Compliance, Otis Johnson, PhD, MPA, founder and principal consultant at Vantix Operations, speaks with Paulo Limgenco, VP of Business Operations and ESG Strategy Lead at YPrime, about how sustainability is shifting from a compliance checkbox to a factor that shapes vendor selection, client trust, and long-term business value.

    Beyond Compliance: YPrime's Paulo Limgenco on Moving ESG From Reporting to Real Business Value

  6. 6d ago

    ACT Brief: Data Pipeline Standardization for Real-Time Analysis, Sponsor Accountability Beyond Contracts, and Autoimmune Pipeline Expansion

    In today's ACT Brief, we examine how data standardization must precede real-time monitoring deployment, why contracts cannot transfer sponsor oversight responsibility, and a strategic acquisition broadening immunology development.

    ACT Brief: Data Pipeline Standardization for Real-Time Analysis, Sponsor Accountability Beyond Contracts, and Autoimmune Pipeline Expansion

  7. Jul 28

    ACT Brief: Data Readiness Gap in Continuous Monitoring, Workflow-Centric AI Deployment, and First-in-Class ADHD Mechanism

    In today's ACT Brief, we examine the data collection-to-analysis gap undermining continuous trial monitoring, why AI agents require foundational workflow infrastructure, and FDA approval of a novel ADHD treatment.

    ACT Brief: Data Readiness Gap in Continuous Monitoring, Workflow-Centric AI Deployment, and First-in-Class ADHD Mechanism

  8. Jul 27

    ACT Brief: Inspection Readiness Throughout Lifecycle, AI Churn and Operational Discipline, and Global Trial Stakeholder Alignment

    In today's ACT Brief, we examine how inspection readiness must accumulate rather than assemble, why AI initiatives stall without disciplined governance, and what US clinical trials need beyond isolated initiatives.

    ACT Brief: Inspection Readiness Throughout Lifecycle, AI Churn and Operational Discipline, and Global Trial Stakeholder Alignment
See All (255)

About

Go behind the pages of Applied Clinical Trials

Information